Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular lymphoma. The EPCORE FL-1 trial results show a 79% progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback